Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity
US-11225673-B2 · Jan 18, 2022 · US
US10072274B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10072274-B2 |
| Application number | US-201715399588-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 5, 2017 |
| Priority date | Nov 21, 2008 |
| Publication date | Sep 11, 2018 |
| Grant date | Sep 11, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.
Opening claim text (preview).
The invention claimed is: 1. A recombinant modified vaccinia Ankara (MVA) virus vector that stably encodes homologous sequences, the vector comprising: first and second nucleotide sequences of at least 2000 nucleotides each, each nucleotide sequence encoding an Ebola virus glycoprotein; wherein one of first and second nucleotide sequences has at least 400 substituted nucleotides and wherein the substituted nucleotides do not alter the amino acids encoded by the first and second nucleotide sequences; wherein the first and second nucleotide sequences differ by at least 400 nucleotides; and wherein the first and second nucleotide sequences share stretches of identity of no more than 10 contiguous nucleotides; and wherein the two Ebola virus glycoprotein nucleotide sequences encode Ebola virus Sudan and Ebola virus Zaire glycoproteins. 2. The recombinant poxviral vector of claim 1 , wherein the first and second nucleotide sequences encode the amino acid sequences of SEQ ID NO: 6 and SEQ ID NO: 7, respectively. 3. The recombinant poxviral vector of claim 2 , wherein the first and second nucleotide sequences comprise the nucleotide sequences of SEQ ID NO: 12 and SEQ ID NO: 13, respectively.
Vectors comprising a coding region that has been codon optimised for expression in a respective host · CPC title
Vaccina virus vectors · CPC title
as vector · CPC title
Poxviral vectors, {e.g. entomopoxvirus} · CPC title
General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.